Altogether, their results suggest that overexpression of RSPO2 could drive a subset of MPNST and that blocking the function of RSPO2 may be a potential therapeutic strategy for MPNST patients with RSPO2 overexpression [72]. Here, RSPO2 is linked to malignant peripheral nerve sheath tumor.